Grant Application Process
The 2022 Call for Proposals for CCF Research, Giant Food NextGen, and Non-Research Grant Awards closed on May 8th, 2022.
The 2022 Call for Proposals for CCF Research, Giant Food NextGen, and Non-Research Grant Awards closed on May 8th, 2022.
The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.
The 17th Annual Hematologic Malignancies Demystified returns in 2025. Access our virtual CME conference and earn CME/CE credits with our renowned faculty. Led by conference…
Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint…
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
China’s NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.
Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.
In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of…
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.